Cannabinoids ? A Significant Psychoactive Herb

posted in: Cannabis 0

Cannabinoids are a group of chemical compounds that include the phytocannabinoids (aromatic hydrocarbon compounds found in cannabis plant) and even includes those chemical compounds that mimic the actions of phytocannabinoids. The most significant natural cannabinoid is the psychoactive tetrahydrocannabinol (delta9-THC). Others like cannabidiol (CBD) and cannabigerol (CBG) are also quite important.

It is important to note that not every observed effects can be attributed to THC as the other constituents may also change its action. Various studies on the same have revealed the fact that CBD reduces anxiety induced by THC. A pure extract of cannabis can therefore be more helpful in practice and clinical trial at state –of-the-art labs can further assess the effectiveness of the same.

Cannabis is quite often utilized by patients suffering from multiple sclerosis (MS) for muscle spasm and pain. Various clinical researches have proved the importance of THC as an analgesic. The same researches have also reveal the fact that CBD and CBG also have analgesic and anti inflammatory qualities that show that there is scope for developing drugs that do not possess the psychoactive properties of THC. Some clinical trials have shown that patients taking the synthetic derivative nabilone for neurogenic pain resorted to herb such as cannabis seeds and found that it relieved not only pain but also anxiety and depression associated with it. cannabinoids are effective in curing vomiting tendency induced by chemotherapy and nabilone has been licensed for this use for many years.

At present, medical scientists are studying the effectiveness of synthetic cannabinoid HU211 as a protective agent after brain trauma. Further studies on cannabis have also proved that it can cure migraine and Tourette’s syndrome, asthma and glaucoma. The safety profile of using cannabis as a medicine for curing the mentioned ailments is quite good. However, smoking the same can lead to various health issues. Even though psychosis has been cited as a result of cannabis abuse, some studies have proved that the same is not related to taking cannabis. However, the same study showed that it may worsen existing symptoms.

Natural substances are highly changeable and multiple components need to up gradate their qualities so as to get the desired effect. Pure natural and synthetic compounds do not have these disadvantages but may not have the overall therapeutic effect of the herb.

Like most substances, Cannabinoids can be exploited to our advantage. However, if we abuse this substance, it can cause various health hazards both physical and mental.

Cannabinoids relieves inflammation, convulsions, nausea, anxiety and it limit’s the growth of cancer cells .To understand and know more about the benefit from the use of cannabis for medicinal purposes, visit http://www.shayanashop.com

Find More Cannabis Articles

Scientific Research and Real Facts about the Cannabinoids in Cannabis

posted in: Cannabis Science 17

PLEASE WATCH AND SHARE THIS VIDEO
NEW Documentary – http://youtu.be/XfO_MpDm5kc
Legalize Cannabis – http://petition.liberal.ca/end-prohibition

Cannabinoid Research

ncbi.nlm.nih.gov/pmc/articles/PMC3442177

ncbi.nlm.nih.gov/pmc/articles/PMC2828614

ncbi.nlm.nih.gov/pmc/articles/PMC2604798

ncbi.nlm.nih.gov/pmc/articles/PMC2872061

ncbi.nlm.nih.gov/pmc/articles/PMC2225529

ncbi.nlm.nih.gov/pmc/articles/PMC2812803

ncbi.nlm.nih.gov/pmc/articles/PMC2277494

ncbi.nlm.nih.gov/pmc/articles/PMC2823358

ncbi.nlm.nih.gov/pmc/articles/PMC2898685

ncbi.nlm.nih.gov/pmc/articles/PMC2925907

ncbi.nlm.nih.gov/pmc/articles/PMC2819831

ncbi.nlm.nih.gov/pmc/articles/PMC2936031

ncbi.nlm.nih.gov/pmc/articles/PMC2866040

ncbi.nlm.nih.gov/pmc/articles/PMC2829220

ncbi.nlm.nih.gov/pmc/articles/PMC3023979

ncbi.nlm.nih.gov/pmc/articles/PMC2936031

ncbi.nlm.nih.gov/pmc/articles/PMC3034694

ncbi.nlm.nih.gov/pmc/articles/PMC3230631

ncbi.nlm.nih.gov/pmc/articles/PMC3232190

ncbi.nlm.nih.gov/pmc/articles/PMC3165947

ncbi.nlm.nih.gov/pmc/articles/PMC3096803

ncbi.nlm.nih.gov/pmc/articles/PMC2071638

ncbi.nlm.nih.gov/pmc/articles/PMC1892413

ncbi.nlm.nih.gov/pmc/articles/PMC2270485

ncbi.nlm.nih.gov/pmc/articles/PMC1592672

ncbi.nlm.nih.gov/pmc/articles/PMC2430692

ncbi.nlm.nih.gov/pmc/articles/PMC2189767

ncbi.nlm.nih.gov/pmc/articles/PMC2664885

ncbi.nlm.nih.gov/pmc/articles/PMC2765124

ncbi.nlm.nih.gov/pmc/articles/PMC2737440

ncbi.nlm.nih.gov/pmc/articles/PMC2955420

ncbi.nlm.nih.gov/pmc/articles/PMC2682269

ncbi.nlm.nih.gov/pmc/articles/PMC2451037

ncbi.nlm.nih.gov/pmc/articles/PMC2592995

ncbi.nlm.nih.gov/pmc/articles/PMC3316151

ncbi.nlm.nih.gov/pubmed/19638490

ncbi.nlm.nih.gov/pubmed/22776349

ncbi.nlm.nih.gov/pubmed/16682966

ncbi.nlm.nih.gov/pubmed/12648025

ncbi.nlm.nih.gov/pubmed/19914218

ncbi.nlm.nih.gov/pubmed/16893424

ncbi.nlm.nih.gov/pubmed/15361550

ncbi.nlm.nih.gov/pubmed/19889794

ncbi.nlm.nih.gov/pubmed/19015962

ncbi.nlm.nih.gov/pubmed/19608284

ncbi.nlm.nih.gov/pubmed/17237277

ncbi.nlm.nih.gov/pubmed/11586361

ncbi.nlm.nih.gov/pubmed/14692532

ncbi.nlm.nih.gov/pubmed/16571653

ncbi.nlm.nih.gov/pubmed/18286801

ncbi.nlm.nih.gov/pubmed/16250836

ncbi.nlm.nih.gov/pubmed/17934890

ncbi.nlm.nih.gov/pubmed/12052046

ncbi.nlm.nih.gov/pubmed/19189054

ncbi.nlm.nih.gov/pubmed/18354058

ncbi.nlm.nih.gov/pubmed/19047095

ncbi.nlm.nih.gov/pubmed/10913156

ncbi.nlm.nih.gov/pubmed/9653194

ncbi.nlm.nih.gov/pubmed/18088200

ncbi.nlm.nih.gov/pubmed/16909207

ncbi.nlm.nih.gov/pubmed/17342320

ncbi.nlm.nih.gov/pubmed/19059457

ncbi.nlm.nih.gov/pubmed/12723496

ncbi.nlm.nih.gov/pubmed/19442536

ncbi.nlm.nih.gov/pubmed/16728591

ncbi.nlm.nih.gov/pubmed/19539619

ncbi.nlm.nih.gov/pubmed/16500647

ncbi.nlm.nih.gov/pubmed/19189659

ncbi.nlm.nih.gov/pubmed/14617682

ncbi.nlm.nih.gov/pubmed/18938775

ncbi.nlm.nih.gov/pubmed/11106791

ncbi.nlm.nih.gov/pubmed/19394652

ncbi.nlm.nih.gov/pubmed/20336665

ncbi.nlm.nih.gov/pubmed/19442435

ncbi.nlm.nih.gov/pubmed/15451022

ncbi.nlm.nih.gov/pubmed/18197164

ncbi.nlm.nih.gov/pubmed/16835997

ncbi.nlm.nih.gov/pubmed/11903061

ncbi.nlm.nih.gov/pubmed/17675107

ncbi.nlm.nih.gov/pubmed/17202146

ncbi.nlm.nih.gov/pubmed/19425170

ncbi.nlm.nih.gov/pubmed/18454173

ncbi.nlm.nih.gov/pubmed/17065222

ncbi.nlm.nih.gov/pubmed/10700234

ncbi.nlm.nih.gov/pubmed/16787257

ncbi.nlm.nih.gov/pubmed/15958274

ncbi.nlm.nih.gov/pubmed/16139274

ncbi.nlm.nih.gov/pubmed/16624285

ncbi.nlm.nih.gov/pubmed/16616335

ncbi.nlm.nih.gov/pubmed/11269508

ncbi.nlm.nih.gov/pubmed/19690545

ncbi.nlm.nih.gov/pubmed/12511587

ncbi.nlm.nih.gov/pubmed/20307616

ncbi.nlm.nih.gov/pubmed/16818634

ncbi.nlm.nih.gov/pubmed/17952650

ncbi.nlm.nih.gov/pubmed/16818650

ncbi.nlm.nih.gov/pubmed/16596790

ncbi.nlm.nih.gov/pubmed/15638794

ncbi.nlm.nih.gov/pubmed/15275820

ncbi.nlm.nih.gov/pubmed/12133838

ncbi.nlm.nih.gov/pubmed/18339876

ncbi.nlm.nih.gov/pubmed/9771884

ncbi.nlm.nih.gov/pubmed/10570948

ncbi.nlm.nih.gov/pubmed/12182964

ncbi.nlm.nih.gov/pubmed/19229996

ncbi.nlm.nih.gov/pubmed/20546877

ncbi.nlm.nih.gov/pubmed/19916793

ncbi.nlm.nih.gov/pubmed/21464819

ncbi.nlm.nih.gov/pubmed/9392925

ncbi.nlm.nih.gov/pubmed/19394652

ncbi.nlm.nih.gov/pubmed/20336665

ncbi.nlm.nih.gov/pubmed/21312237

ncbi.nlm.nih.gov/pubmed/23318578

ncbi.nlm.nih.gov/pubmed/21807457

ncbi.nlm.nih.gov/pubmed/21298280

ncbi.nlm.nih.gov/pubmed/22447182

ncbi.nlm.nih.gov/pubmed/23361273

ncbi.nlm.nih.gov/pubmed/16500647

google.com/patents/US4837228

google.com/patents/US4189491

google.com/patents/US5631297

google.com/patents/US6132762

google.com/patents/US6410588

google.com/patents/US6630507

google.com/patents/US7741365

google.com/patents/US7597910

google.com/patents/US8071641

google.com/patents/US8242178

google.com/patents/US8034843

cmcr.ucsd.edu

phoenixtears.ca

thesethgroup.org

herb.com/guzman.pdf

cannabis-med.org/index.php?lng=en

gwpharm.com/cannabinoids-science.aspx

phoenixtearsfoundation.com/scientific-studies
Video Rating: 4 / 5

Despite Legalization, Not Much Known About Effects

posted in: Cannabis News 0

Even though 20 states, including Illinois, have passed laws legalizing medical marijuana, swayed in part by thousands of personal testimonies, current research hasn’t nailed down exactly if, and how, marijuana alleviates all the specific diseases the drug is being legalized to treat, experts say.

A number of proponents believe marijuana could benefit people with everything from glaucoma to cancer, and it’s been legalized in Illinois to aid patients with some 40 medical conditions. But opponents of its medicinal use believe the risks of smoking medical marijuana outweigh the benefits, while others question whether patients really improve or only feel like they improve.

Marijuana’s best-known compound is THC, but the plant actually has 105 unique cannabis compounds with potential for medicinal use, proponents say. THC has already been approved by the Food and Drug Administration in synthetic form to help patients with nausea and decreased appetite.

Some scientists believe the plant’s other compounds — called cannabinoids — could have equal promise. Although research has increased in recent years as more states legalize medical marijuana, solid evidence of how individual cannabinoids could help people with specific diseases has been significantly lacking, a review of medical literature and interviews with experts shows.

Researching the potential effects of marijuana’s various components on conditions such as multiple sclerosis, fibromyalgia or lupus could have serious implications for doctors who want to prescribe medical marijuana to patients.

If the specific benefits could be proved, experts say, doctors ultimately would be able to assign particular strains — with varying chemical mixes — to people, depending on their condition. Further research also may help determine optimal doses and whether marijuana works better than other medicines, experts say.

While most medicines derived from nature are tested before they reach the masses, the process to evaluate marijuana has been confounded by its longtime status as an illegal drug, which it retains in the eyes of the federal government. A complicated federal approval process and limited availability of research-grade marijuana add to the difficulty.

The only study specifically cited in Illinois’ law, signed by Gov. Pat Quinn in August and set to go into effect next year, is a 1999 Institute of Medicine report. But Dr. John Benson, a lead editor of the report, said legislators stretched the conclusion of the book-length study when it said modern medical research “has confirmed the beneficial uses of cannabis.”

While the report did say there was promise that marijuana could have medical benefits, it also suggests researchers need to continue to dig deeper into the issue. It also says marijuana should not be smoked, he said.

“Smoking marijuana is not recommended,” the report states. “The long-term harm caused by smoking marijuana makes it a poor delivery system.”

The 14-year-old article has become a primary source for both critics and supporters of medical marijuana — the Drug Enforcement Agency and advocacy groups have cited it to prove opposite points.

“I don’t think whatever the legislature is saying (in the law) is in effect untrue,” Benson, now retired, said from his California home, “but it needs to be qualified.”

Medicine by Legislation

Illinois legislators knew they had an uphill battle getting the medical marijuana bill passed last summer, Rep. Lou Lang said. Lang worked at swaying his colleagues for five years and said he compromised on the list of about 40 conditions — some of which are closely related — that will qualify people for medical marijuana once it becomes available sometime next year.

Illinois legislators, he said, did “a substantial amount of reading,” but they did not evaluate each condition on the list with any scientific methodology.

“I can’t point to specific studies that we used,” Lang said. “Much of it was done by patients telling us what worked and what didn’t. … It became crystal clear some of these things that ought to be in the bill.”

The legislators relied mostly on personal testimonies and compared notes with states that have also passed medical marijuana laws.

“When thousands of people come to me and say they’re using this drug illegally because it’s the only thing that works,” Lang said, “that’s good enough for me.”

Mike Graham, of Manteno, was one person who shared his story with legislators. A little more than a decade ago, he was using 14 different pharmaceuticals. Living with an extremely painful degenerative spine disease, he has been through multiple surgeries in efforts to remedy it. But doctors feared one more could paralyze him, so he took medications for pain instead.

“I didn’t even know my name,” Graham said. “It was horrid.”

When he was in his late 30s, doctors sent him home with a hospice care nurse. After reviewing his medications, she told him he would die early if he continued taking all of them. To his surprise, she recommended pot, he said.

“I almost fell out of bed laughing,” Graham, 51, said. “I come from a law enforcement family.”

Increasingly desperate, in 2002, he decided to give it a try. He was able to cut back on all his previous medications except a morphine pump under his skin. Now, he takes three or four puffs of marijuana in the morning and at night. Once down to 135 pounds, the more than 6-foot-tall Graham now says he’s back up to 250 after regaining his appetite.

“What it comes down to here (is) I wouldn’t be here if I hadn’t made that decision,” Graham said.

While stories like Graham’s are plentiful, doctors and researchers say the nonmedical elements of the plant could have sometimes serious adverse effects.

Dr. Eric Voth, a Topeka, Kan., internist and pain specialist and chairman of the Institute on Global Drug Policy, said relying on anecdotal evidence is dangerous because other factors could influence why patients start to feel better.

“It’s very hard to differentiate whether somebody feels better because they’re stoned or because they’re getting a true therapeutic benefit from the drug,” Voth said.

Health Risks

Smoking marijuana could increase the risk of cancer because of inhalation of tar and other carcinogens in the plant, Voth said. While proponents of its use point to the 105 unique compounds, as detailed in a soon-to-be published report by leading cannabinoid researcher Dr. Mahmoud ElSohly and his colleagues, that may be useful for medicine, there are hundreds more compounds in marijuana that some scientists believe not only have no use but may be harmful.

“You’ve still got (hundreds of other) substances in there,” Voth said. “It just (shouldn’t) be smoked. That is a crazy precedent.”

Illinois’ law allows dispensaries to sell marijuana-infused baked goods in addition to joints, but advocates say it takes longer to feel the effects of marijuana when it’s ingested instead of smoked.

Several papers in scientific journals have found that marijuana use over a long period of time can have negative cognitive effects too. Users can’t concentrate or remember as well as before, in some cases years after they have quit.

Joe Friedman, a Deerfield pharmacist, said the chemical makeup of marijuana could be tested at independent labs, and he hopes it will be in Illinois. Marijuana is designated as a Schedule I drug, defined by the DEA as “drugs with no currently accepted medical use and a high potential for abuse.”

Changing it to a Schedule II drug, which means it is considered dangerous but could have potential medicinal value, Friedman said, would help research progress in learning which type of marijuana is best for which patient.

“When a drug comes on the market, you take the active ingredients, you figure out what these drugs do,” said Friedman, who wants to open a dispensary in Illinois. “You want to be able to identify the active ingredients and the concentrations … and then down the line (after more research is done), you’ll be able to say, ‘OK this one is good for MS,’” Friedman said.

But Voth said he doubts that even identifiable benefits would be enough to outweigh the negative effects, because of other potentially harmful components that are mixed in.

“Essentially what they are, are toxic chemicals,” Voth said. “None of those things would you ever mix with medicine.”

What Some Call a Cure-All

In 1937, the U.S. criminalized marijuana, and today it’s considered a Schedule I drug, along with heroin and LSD.

The FDA approved a synthetic THC pill called Marinol in 1985, acknowledging the drug’s benefits for people with nausea and decreased appetite. In Canada and some parts of Europe, a similar drug called Sativex — containing synthetic THC and cannabidiol — has been approved in recent years, offered as an oral spray. In the late 1980s, scientists discovered a previously unknown biological system called the endocannabinoid system, which proponents for marijuana theorize could show how it works.

The National Institutes of Health reported in 2006 that the system holds “therapeutic promise in a wide range of disparate diseases.”

But experts say more research is needed before determining exactly what the system may be able to do.

Mary Lynn Mathre, a founding partner of Patients Out of Time, a marijuana advocacy group that focuses on health issues, said the leading theory regarding the system is that the human body has cannabinoid receptors — essentially key holes that cannabis compounds fit into, helping the body regulate.

“You take cannabis, which has similar chemicals that we need, and you put it in the body and they work if we’re not making the cannabinoids that we need,” explained Mathre, a longtime registered nurse. “You can liken this to a diabetic. Their pancreas isn’t making insulin, so we give them insulin. If our body can’t make this chemical, there happens to be this plant on earth that is there to supply us.”

A Call for Research

Many prominent health organizations — including the American Medical Association, the American Cancer Society and the National Multiple Sclerosis Society — support researching cannabinoids’ potential but don’t endorse the legalization of medical marijuana. The American Nurses Association and the American College of Physicians support medical marijuana’s legalization, while also calling for more research.

“Science has been doing this kind of thing for years,” Voth said. “They find a (naturally) occurring substance and then they try to dissect down to what really works, isolate it and synthesize it. That’s what pharmaceutical companies do all the time.”

While THC has a few proven medical benefits, it’s possible that other compounds that don’t have the same euphoric effect could relieve symptoms just as well or better than THC, researchers and pharmacists say.

Pritesh Kumar, a researcher who specializes in cannabinoid pharmacology and is a consultant for Chicago-based Quantum 9, a medical marijuana technology firm, has focused on CBD, a compound in marijuana some scientists believe could have significant benefits.

Research like Kumar’s, studying isolated compounds in marijuana, has picked up in recent years, but widespread research looking at how specific diseases and cannabinoids interact has not been done.

Friedman, the Deerfield pharmacist, said he’s hopeful that with medical marijuana legalization on a faster track than ever, disease-specific research in the U.S. will pick up.

“As marijuana gains popularity and (if it) moves from Schedule I to Schedule II, research will really kick in,” Friedman said. “This is a whole new industry, and this is going to get bigger and stronger as time goes on.”

Source: Chicago Tribune (IL)
Author: Ellen Jean Hirst, Tribune Reporter
Published: October 27, 2013
Copyright: 2013 Chicago Tribune Company, LLC
Website: http://www.chicagotribune.com/

Marijuana Compounds Can Kill Some Cancer Cells

posted in: Cannabis News 0

A scientist in the United Kingdom has found that compounds derived from marijuana can kill cancerous cells found in people with leukemia, a form of cancer that is expected to cause an estimated 24,000 deaths in the United States this year.

“Cannabinoids have a complex action; it hits a number of important processes that cancers need to survive,” study author Dr. Wai Liu, an oncologist at the University of London’s St. George medical school, told The Huffington Post. “For that reason, it has really good potential over other drugs that only have one function. I am impressed by its activity profile, and feel it has a great future, especially if used with standard chemotherapies.”

Liu’s study was recently published in the journal Anticancer Research. It was supported by funding from GW Pharmaceuticals, which already makes a cannabis-derived drug used to treat spasticity caused by multiple sclerosis.

The study looked at the effects of six different non-psychoactive cannabinoids — compounds derived from marijuana that do not cause the “high” associated with its THC ingredient — when applied alone, and in combination, to leukemia cells. Cannabinoids displayed a “diverse range of therapeutic qualities” that “target and switch off” pathways that allow cancers to grow, Liu told U.S. News & World Report.

In an interview with The Huffington Post, Liu stressed that that his research was built around the testing of the six purified cannabinoid forms — not traditional cannabis oil, which Liu described as “crude” in comparison and generally containing 80-100 different cannabinoids. “We do not really know which are the ones that will be anticancer and those that may be harmful,” Liu said.

During the study, Liu and his team grew leukemia cells in a lab and cultured them with increasing doses of the six pure cannabinoids, both individually and in combination with each other. His study says the six cannabinoids were CBD (Cannabidiol), CBDA (Cannabidiolic acid), CBG (Cannbigerol), CBGA (Cannabigerolic acid), CBGV (Cannabigevarin) and CBGVA (Cannabigevaric acid). Liu and his team then assessed the viability of the leukemia cells and determined whether or not the cannabinoids destroyed the cells or stopped them from growing.

Although promising, Liu also said that it remains unclear if the cannabinoid treatment would work on the 200-plus existing types of cancer.

“Cancer is an umbrella term for a range of diseases that fundamentally differ in their cellular makeup, [and] which occur as a result of disturbances to growth controls,” Liu said. “Chemotherapy works by disrupting these dysfunctional growth signals. Therefore, any cancers that have these profiles should respond to the chemotherapy. It just so happens that a number of cannabinoids can target these very same mechanisms that make cancer what it is, and so any cancer that exhibits these faults should respond well to cannabinoids. The flip side is, of course, that other cancers may not have these same genetic faults and so cannabinoids may not work as well.”

According to the Centers for Disease Control, 7.6 million people die from various forms of cancer each year worldwide.

When asked if smoking marijuana has the same or similar effects as ingesting the pure cannabinoid compounds he studied, Liu said he thinks it’s unlikely.

“Smoking cannabis introduces a number of potential problems,” Liu said. “First, the complex makeup of cannabis that contains about 80 bioactive substances means that the desired anticancer effect may be lost because these compounds may interfere with each other. Second, we see that delivering the drug either by injection or by a tablet would ensure the most effective doses are given. Smoking would be variable, and indeed the heat of the burning may actually destroy the useful nature of the compounds.”

In 2012, researchers at the California Pacific Medical Center in San Francisco found that CBD (cannbidiol), a non-toxic, non-psychoactive chemical compound found in the cannabis plant, could stop metastasis in many kinds of aggressive cancer.

The National Cancer Institute has also funded some research into cannabis and cancer, including a 2012 study that looked at the effects cannabis compounds have on slowing the progression of breast cancer, spokesman Michael Miller told U.S. News and World Report. However NCI has not funded research on the effects of cannabinoids on leukemia.

Liu stressed that much work is still needed, and said that finding support for marijuana-derived medicines can be polarizing.

“Although there is much promise, I struggle to find enough support to drive this work on,” Liu said. “The mention of cannabinoids can polarize the public, who understandably link cannabis smoking with cannabis-derived drugs.”

Liu told the Seattle PI’s Pot Blog that he hopes to start clinical trials involving humans in 12 to 18 months.

Source: Huffington Post (NY)
Author: Matt Ferner, The Huffington Post
Published: October 25, 2013
Copyright: 2013 HuffingtonPost.com, LLC
Contact: [email protected]
Website: http://www.huffingtonpost.com/